Cookies Policy
X

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

I accept this policy

Find out more here

EU Marketing Authorisation of Orphan Medicinal Products and Its Impact on Related Research

No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
The full text of this article is not currently available.

Brill’s MyBook program is exclusively available on BrillOnline Books and Journals. Students and scholars affiliated with an institution that has purchased a Brill E-Book on the BrillOnline platform automatically have access to the MyBook option for the title(s) acquired by the Library. Brill MyBook is a print-on-demand paperback copy which is sold at a favorably uniform low price.

Access this article

+ Tax (if applicable)
Add to Favorites
You must be logged in to use this functionality

Over the last 15 years, there has been a steady increase in the development of orphan medicinal products (OMPs). This raises an important question: What impact does the EU marketing authorisation of an OMP have on related research? This article establishes that the key orphan incentive, namely the 10‑year market exclusivity provision laid down in Article 8 of the EU Regulation on OMPs (Regulation 141/2000), has a huge potential impact on related research. It is argued that this provision can make it too difficult for researchers/sponsors to attain marketing approval for closely related products. This article advances two proposals to address this problem. First, it argues for new principles for assessing similarity, so as to clarify and narrow the ambit of market exclusivity. Secondly, it argues for improved conditions for a demonstration of ‘clinical superiority’ for similar OMPs.

Affiliations: 1: General Manager, Institute for German, European and International Medical Law, Public Health Law and Bioethics, Universities of Heidelberg and MannheimGermany ; 2: Professor of Medical Law and Ethics, Durham UniversityUK

* We would like to thank Robert Schütze for his advice on the general principles of EU law and Emma Cave for her helpful comments. We remain responsible for any errors.
Loading

Full text loading...

/content/journals/10.1163/15718093-12341439
Loading

Data & Media loading...

http://brill.metastore.ingenta.com/content/journals/10.1163/15718093-12341439
Loading

Article metrics loading...

/content/journals/10.1163/15718093-12341439
2017-11-10
2017-11-19

Sign-in

Can't access your account?
  • Tools

  • Add to Favorites
  • Printable version
  • Email this page
  • Subscribe to ToC alert
  • Get permissions
  • Recommend to your library

    You must fill out fields marked with: *

    Librarian details
    Your details
    Why are you recommending this title?
    Select reason:
     
    European Journal of Health Law — Recommend this title to your library
  • Export citations
  • Key

  • Full access
  • Open Access
  • Partial/No accessInformation